SCHEDULE: Armistice Capital Reports 9.99% Stake in Arcadia Biosciences

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting a beneficial ownership of 9.99% in Arcadia Biosciences, Inc.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly filed an amended Schedule 13G, indicating their beneficial ownership of 267,392 shares of common stock in Arcadia Biosciences, Inc.
• This holding represents 9.99% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.
• The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a passive ownership stake without significant strategic implications or new developments.

Positives

• Armistice Capital has taken a significant passive stake (9.99%) in Arcadia Biosciences, which could signal confidence in the company's long-term prospects from an institutional investor.
• The filing confirms that the shares were acquired and are held in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Negatives

• The filing is an amendment to a previous filing, suggesting no new strategic action or significant change in ownership percentage beyond what was previously reported.
• The passive nature of the ownership (no sole voting or dispositive power reported for the entities themselves) limits immediate positive impact on the company's strategic direction.

Risks

• While the filing states the shares are not held for the purpose of changing or influencing control, any future increase in stake or change in investment strategy could pose a risk to existing management.
• The Master Fund, the direct holder, disclaims beneficial ownership due to its investment management agreement with Armistice Capital, which could introduce complexity in governance discussions.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Armistice Capital's continued passive investment in Arcadia Biosciences, a company operating in the agricultural technology sector.

Stakeholder Impact

• Shareholders: The passive stake by Armistice Capital may be viewed positively as a sign of institutional interest, but the lack of active involvement limits immediate impact on share price or corporate strategy.
• Management: The filing reaffirms that the investment is not intended to influence control, providing some stability for current management.
• Creditors: No direct impact is indicated.

Next Steps

• Armistice Capital will continue to hold its shares in Arcadia Biosciences, Inc.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership.

Key Dates

Keywords

Arcadia Biosciences, Schedule 13G, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, Investment Management